These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 34098591)

  • 1. An Impaired Inflammatory and Innate Immune Response in COVID-19.
    Park SH
    Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
    Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
    Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
    Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
    Front Immunol; 2021; 12():629193. PubMed ID: 33732251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
    Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
    Shawki MA; Elsayed NS; Mantawy EM; Said RS
    Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role and delicate balance of Host Immunity in Coronavirus Disease-19.
    Vyas AK; Varma V; Garg G; Gupta P; Trehanpati N
    Iran J Immunol; 2021 Mar; 18(1):1-12. PubMed ID: 33787510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
    Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
    Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
    Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
    Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
    La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
    Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.
    Jung HE; Lee HK
    Viruses; 2021 Oct; 13(11):. PubMed ID: 34834939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune dysregulation and system pathology in COVID-19.
    Jamal M; Bangash HI; Habiba M; Lei Y; Xie T; Sun J; Wei Z; Hong Z; Shao L; Zhang Q
    Virulence; 2021 Dec; 12(1):918-936. PubMed ID: 33757410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines.
    Zheng M; Karki R; Williams EP; Yang D; Fitzpatrick E; Vogel P; Jonsson CB; Kanneganti TD
    Nat Immunol; 2021 Jul; 22(7):829-838. PubMed ID: 33963333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
    Zarei M; Sahebi Vaighan N; Ziai SA
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets.
    Ruenjaiman V; Hirankarn N; Palaga T
    Asian Pac J Allergy Immunol; 2021 Jun; 39(2):69-77. PubMed ID: 34174806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein as an effector molecule in Covid-19 pathogenesis.
    Mosquera-Sulbaran JA; Pedreañez A; Carrero Y; Callejas D
    Rev Med Virol; 2021 Nov; 31(6):e2221. PubMed ID: 34773448
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
    Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19
    Vignesh R; Swathirajan CR; Tun ZH; Rameshkumar MR; Solomon SS; Balakrishnan P
    Front Immunol; 2020; 11():607734. PubMed ID: 33569053
    [No Abstract]   [Full Text] [Related]  

  • 20. Nexus between COVID-19 and periodontal disease.
    Sukumar K; Tadepalli A
    J Int Med Res; 2021 Mar; 49(3):3000605211002695. PubMed ID: 33745336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.